Osmond D H, Cooper R M
Can J Physiol Pharmacol. 1978 Oct;56(5):792-805. doi: 10.1139/y78-125.
Plasma and serum of healthy subjects apparently contain a precursor form of renin, or 'prorenin,' which can be activated by the ice-cold temperature at which samples are customarily handled for prolonged periods in laboratories and blood banks. The effect of such prior cryoactivation for 9 days at 4 degrees C is to increase subsequent plasma renin activity (PRA) at 37 degrees C by 108 +/- 16.3% (mean +/- SE) over the nonactivated control value (P less than 0.001). At a lower temperature (-4 degrees C), the cryoactivation effect is considerably greater than at 4 degrees C. Cryoactivation is not obliterated by the prefreezing of plasma, or reduced by inclusion of bacteriostats. Nor is it attributable to any detectable reduction in angiotensinase activity. In rats, cryoactivation at 4 degrees C is much lower than in humans, suggesting a marked species difference either in prorenin concentration or in the rapidity of its spontaneous conversion after blood collection. Trypsin at near optimal concentrations also consistently activates human plasma prorenin, whether at 4, 23, or 37 degrees C indicating that cold is not an essential concomitant of tryptic activation. In excess, the magnitude of which varies among individuals, trypsin at first produces activation and later a decline in PRA, probably due to degradation of the reactants (prorenin, renin, angiotensinogen) and of the initial product (angiotensin I). The identity of angiotensin I in activated and control plasmas can be established by specific radioimmunoassay, and bioassay. Our data indicate that tryptic activation involves little direct production of angiotensin I but rather converts prorenin, thereby enhancing the angiotensin generating capacity of the plasma renin system itself. Tryptic activation in plasma of anaesthetized dogs is lower than in humans, but higher than in conscious or anaesthetized rabbits in whom the effect appears to be slight. In anaesthetized rats there is virtually no tryptic activation, which is in line with the results by cryoactivation. Since the renin--angiotensin systems of dogs, rabbits, and rats have been extensively studied in experimental models of human hypertension, these observed departures from human levels of cryoactivation and tryptic activation of prorenin deserve further investigation.
健康受试者的血浆和血清中显然含有肾素的前体形式,即“前肾素”,它可被冰冷温度激活,而在实验室和血库中,样本通常会在这种温度下长时间处理。在4℃下进行9天的这种预先冷冻激活的效果是,与未激活的对照值相比,37℃时随后的血浆肾素活性(PRA)增加了108±16.3%(平均值±标准误)(P<0.001)。在较低温度(-4℃)下,冷冻激活效果比在4℃时显著更大。血浆预冻不会消除冷冻激活效果,加入抑菌剂也不会使其降低。这也不归因于血管紧张素酶活性的任何可检测到的降低。在大鼠中,4℃下的冷冻激活比在人类中低得多,这表明在前肾素浓度或采血后其自发转化的速度方面存在明显的物种差异。接近最佳浓度的胰蛋白酶也始终能激活人血浆前肾素,无论在4℃、23℃还是37℃,这表明寒冷并非胰蛋白酶激活的必要伴随因素。过量的胰蛋白酶(其程度因人而异)起初会产生激活作用,随后PRA下降,这可能是由于反应物(前肾素、肾素、血管紧张素原)和初始产物(血管紧张素I)的降解。通过特异性放射免疫测定和生物测定可以确定激活血浆和对照血浆中血管紧张素I的一致性。我们的数据表明,胰蛋白酶激活几乎不会直接产生血管紧张素I,而是转化前肾素,从而增强血浆肾素系统本身的血管紧张素生成能力。麻醉犬血浆中的胰蛋白酶激活低于人类,但高于清醒或麻醉的兔子,在兔子中这种效果似乎很轻微。在麻醉大鼠中几乎没有胰蛋白酶激活,这与冷冻激活的结果一致。由于在人类高血压实验模型中对犬、兔和大鼠的肾素 - 血管紧张素系统进行了广泛研究,这些观察到的前肾素冷冻激活和胰蛋白酶激活水平与人类水平的差异值得进一步研究。